SPEAR UltraDetect™ pTau 231 Biomarker Assay Kit
The SPEAR UltraDetect™ pTau 231 biomarker assay kit is highly sensitive and ideal for Alzheimer’s research using plasma samples. Requires SPEAR UltraDetect™ Reaction Kit. For research use only.
Receive your quote directly from the manufacturer.
A blood biomarker of early-stage amyloid pathology
pTau231 (phosphorylated tau at threonine 231) is a blood-based biomarker that reflects early tau phosphorylation changes associated with amyloid-β pathology. It correlates with brain amyloid status as measured by PET and CSF. pTau 231 is one of the earliest tau epitopes to phosphorylate in Alzheimer’s disease suggesting strong potential for detecting preclinical Alzheimer’s disease. pTau 231 is used in research for early disease detection, risk stratification, and to study the temporal sequence of amyloid and tau pathology.
Unparalleled Sensitivity with SPEAR UltraDetect pTau 231
The SPEAR UltraDetect pTau 231 assay demonstrates unparalleled sensitivity, delivering high quantifiability – important for exploration of pTau 231 as an early marker in longitudinal studies and potential applications in clinical trials.
In a study comparing a cohort of PET-confirmed amyloid positive and amyloid negative patient samples, SPEAR UltraDetect quantified 100% of samples – including amyloid negative samples with average CV of 5%.
